Abstract:Abstract Background/Aims Age has a significant impact on SLE. However, data on very late onset SLE (vlSLE) patients are scarce. We have characterized a large SLE patient cohort, followed for up to 45 years and compared the clinical and serological features at the different ages at diagnosis, focusing on those whose disease began at 60 or later. Methods We conducted an observational cross-sectional study at our SLE clinic. All patients with an SLE diagnosis evaluated from January 1978 to May 2023 were included. Patients were divided into four groups according to age at diagnosis: juvenile SLE (jSLE - <18 years); adult SLE (aSLE - 18-49 years); late SLE (lSLE - 50-59 years); vlSLE (≥ 60 years). Proportions and median values were compared using the X2 and Kruskall-Wallis tests, respectively. The probability of survival was estimated using the Kaplan-Meier method. Results 845 patients were enrolled. jSLE, aSLE, lSLE, and vlSLE groups included 153 (18.1%), 630 (74.6%), 47 (5.56%), and 15 (1.78%) patients, respectively. The mean age at diagnosis in vlSLE patients was 66.7 years. The female-to-male ratio tended to fall in the vlSLE group (4:1; p=0.282). vlSLE patients were mainly caucasian (93.3%; p<0.001) and had the lowest survival time (20.3 years; p<0.001). The most frequent clinical feature at follow-up in all groups was arthritis. Nevertheless, arthritis was least common among vlSLE patients (73.3%; p=0.043). Although malar and/or discoid rash, photosensitivity, and alopecia were less frequent among lSLE and vlSLE patients, the difference was not statistically significant. In contrast, oral ulcers tended to be more frequent in vlSLE patients (33.3%; p=0.537). vlSLE patients more commonly developed Sjögren’s syndrome (SS - 33.3%; p<0.001) and rheumatoid arthritis (RA - 13.3%; p<0.001). The prevalence of anti-phospholipid syndrome did not differ significantly between age groups. Neuropsychiatric involvement, and myositis did not occur among vlSLE patients. At diagnosis, vlSLE patients had the lowest prevalence of positive anti-dsDNA antibodies (26.7%; p=0.010) and low C3 levels (13.3%; p<0.001). Anti-SSA/Ro antibody positivity was also least common among vlSLE patients (26.7%; p=0.045). Although vlSLE patients also tended to have the lowest levels of ANA and anti-SSB/La antibody positivity, the difference was not statistically significant. Rheumatoid factor levels tended to increase with increasing age (p=0.066). Conclusion We report a detailed analysis of a large SLE under long term follow-up focusing on age at diagnosis related differences. Elderly patients differ from younger patients in clinical presentation. In vlSLE, female predominance is less pronounced; arthritis, anti-dsDNA antibodies and low C3 levels are less frequent. Concomitant SS and RA are more common. Our results confirm that older-onset SLE patients have lower disease activity. Nevertheless, these patients have the lowest survival rate. While very uncommon, SLE should not be excluded as a possible diagnosis in the elderly. Disclosure L. Viveiros: None. A. Neves: None. D.A. Isenberg: None.

Research progress on clinical features,diagnosis and treatment of late-onset systemic lupus erythematosus

Immunological pathogenesis and treatment of systemic lupus erythematosus

Long Non-Coding RNAs in Systemic Lupus Erythematosus: New Insights into Disease Pathogenesis and Diagnosis.

169 Clinical and Laboratory Features of Late-Onset Systemic Lupus Erythematosus in a Chinese Population

Survival analysis of late-onset systemic lupus erythematosus: a cohort study in China

Clinical patterns of disease: From early systemic lupus erythematosus to late-onset disease

Associations of Clinical Features and Prognosis with Age at Disease Onset in Patients with Systemic Lupus Erythematosus.

A Comprehensive Review of Immune-Mediated Dermatopathology in Systemic Lupus Erythematosus.

Clinical and Pathological Features of Patients with Late-on Set Lupus Nephritis

Recent Advances in Understanding Pathogenesis and Therapeutic Strategies of Systemic Lupus Erythematosus

A Contemporary Update on the Diagnosis of Systemic Lupus Erythematosus.

Comparison of late-onset and non-late-onset systemic lupus erythematosus individuals in a real-world electronic health record cohort

Difference and connection of clinical features and ANA patterns in new-onset SLE cross age groups

Progress of Therapy for Systemic Lupus Erythematosus

Characteristic features of late-onset systemic lupus erythematosus: An observational study of data from the Lupus Registry of Nationwide Institutions

P152 Very Late Onset Systemic Lupus Erythematosus - Comparison with Younger Patients

A large cohort comparison of very late-onset systemic lupus erythematosus with younger-onset patients

Analysis on the Risk Factors of Infection in Late-onset Systemic Lupus Erythematosus Patients

Clinical and laboratorial outcome of different age-onset systemic lupus erythematosus patients in Jiangsu, China: a multicentre retrospective study

Research Progress in Systemic Lupus Erythematosus from 2021 to 2022

Current Status and Challenges in Diagnosis and Treatment of Systemic Lupus Erythematosus in China